| Literature DB >> 29163437 |
Marta Schielmann1, Piotr Szweda1, Katarzyna Gucwa1, Marcin Kawczyński2, Maria J Milewska2, Dorota Martynow1, Joachim Morschhäuser3, Sławomir Milewski1.
Abstract
Oligopeptides incorporating N3-(4-methoxyfumaroyl)-L-2,3-diaminopropanoic acid (FMDP), an inhibitor of glucosamine-6-phosphate synthase, exhibited growth inhibitory activity against Candida albicans, with minimal inhibitory concentration values in the 0.05-50 μg mL-1 range. Uptake by the peptide permeases was found to be the main factor limiting an anticandidal activity of these compounds. Di- and tripeptide containing FMDP (F2 and F3) were transported by Ptr2p/Ptr22p peptide transporters (PTR) and FMDP-containing hexa-, hepta-, and undecapeptide (F6, F7, and F11) were taken up by the oligopeptide transporters (OPT) oligopeptide permeases, preferably by Opt2p/Opt3p. A phenotypic, apparent resistance of C. albicans to FMDP-oligopeptides transported by OPT permeases was triggered by the environmental factors, whereas resistance to those taken up by the PTR system had a genetic basis. Anticandidal activity of longer FMDP-oligopeptides was strongly diminished in minimal media containing easily assimilated ammonium sulfate or L-glutamine as the nitrogen source, both known to downregulate expression of the OPT genes. All FMDP-oligopeptides tested were more active at lower pH and this effect was slightly more remarkable for peptides F6, F7, and F11, compared to F2 and F3. Formation of isolated colonies was observed inside the growth inhibitory zones induced by F2 and F3 but not inside those induced by F6, F7, and F11. The vast majority (98%) of those colonies did not originate from truly resistant cells. The true resistance of 2% of isolates was due to the impaired transport of di- and to a lower extent, tripeptides. The resistant cells did not exhibit a lower expression of PTR2, PTR22, or OPT1-3 genes, but mutations in the PTR2 gene resulting in T422H, A320S, D119V, and A320S substitutions in the amino acid sequence of Ptr2p were found.Entities:
Keywords: Candida albicans; antifungals; oligopeptides; permease; resistance mechanism
Year: 2017 PMID: 29163437 PMCID: PMC5673977 DOI: 10.3389/fmicb.2017.02154
Source DB: PubMed Journal: Front Microbiol ISSN: 1664-302X Impact factor: 5.640
Candida albicans strains used in this study.
| Strain | Parent | Genotype or description | Reference |
|---|---|---|---|
| ATCC 10231 | Wild type reference strain | - | |
| SC5314 | Wild type reference strain | ||
| SC5314 | opt1-1Δ::FRT/opt1-2Δ::FRT | ||
| SC5314 | opt23-1Δ::FRT/opt23-2Δ::FRT | ||
| SC5314 | opt4-1Δ::FRT/opt4-2Δ::FRT | ||
| SC5314 | opt5-1Δ::FRT/opt5-2Δ::FRT | ||
| SC5314 | opt6Δ::FRT/opt6Δ::FRT | ||
| SC5314 | opt7Δ::FRT/ opt7Δ::FRT | ||
| SC5314 | opt8-1Δ::FRT/opt8-2Δ::FRT | ||
| SC5314 | opt1-1Δ::FRT/opt1-2Δ::FRT | ||
| opt23-1Δ::FRT/opt23-2Δ::FRT | |||
| opt4-1Δ::FRT/opt4-2Δ::FRT | |||
| opt5-1Δ::FRT/opt5-2Δ::FRT | |||
| SC5314 | ptr2-1Δ::FRT/ptr2-2Δ::FRT | ||
| ptr22Δ::FRT/ptr22Δ::FRT | |||
| SC5314 | opt1-1Δ::FRT/opt1-2Δ::FRT | ||
| opt23-1Δ::FRT/opt23-2Δ::FRT | |||
| opt4-1Δ::FRT/opt4-2Δ::FRT | |||
| opt5-1Δ::FRT/opt5-2Δ::FRT | |||
| ptr2-1Δ::FRT/ptr2-2Δ::FRT | |||
| ptr22Δ::FRT/ptr22Δ::FRT |
Primers used for RT-PCR and in PCR gene amplification for sequencing.
| No | Gene | Name | Primer sequence |
|---|---|---|---|
| Primers for RT-PCR | |||
| 1 | OPT1RTPCRFor | 5′-GTATGATGTTGTTCAAGACCTTCGGATAC-3′ | |
| 2 | OPT1RTPCRRev | 5′-GCAGCAAACTGCGCCCAAAAC-3′ | |
| 3 | OPT2RTPCRFor | 5′-CCAAAACCTTGCAGTAGTCACTGG-3′ | |
| OPT2RTPCRRev | 5′-GTTAACTGGATTGAAAAATGGTACCTG-3′ | ||
| OPT3RTPCRFor | 5′-GGACAGGATATTTACCAATCAACGATAATGG-3′ | ||
| OPT3RTPCRRev | 5′-AACCAAGTTGGCAGCGGTATAG-3′ | ||
| 4 | PTR2RTPCRFor | 5′-ATGAGCAATCACCATGTGATAC-3′ | |
| 5 | PTR2RTPCRRev | 5′-ATGCAGCGGAGAAAGCAGAC-3′ | |
| PTR22RTPCRFor | 5′-CTTACTTGCTTACGTTCTGCTTCTTC-3′ | ||
| PTR22RTPCRRev | 5′-CCGTTTATGATACCGACCCAAACAC-3′ | ||
| Primers for PCR gene amplification | |||
| 1 | OPT1S1For | 5′-CACTATTGATTCCATTCCTAACATT-3′ | |
| OPT1S1Rev | 5′-CAACGATGCGATAAGGTCAC-3′ | ||
| OPT1S2For | 5′-ATCCACCACCTTTGCC-3′ | ||
| 2 | OPT1S2Rev | 5′-GCAATAATGTGTGTTTGTGTG-3′ | |
| 3 | OPT2S1For | 5′-ATGGTTTTAAAAGATTGCAAATTG-3′ | |
| OPT2S1Rev | 5′-GTTAACTGGATTGAAAAATGGTACCTG-3′ | ||
| OPT2S2For | 5′-CCAAAACCTTGCAGTAGTCACTGG-3′ | ||
| OPT2S2Rev | 5′-CTAAGGGAAATGACCGATCCTTGG-3′ | ||
| OPT3S1For | 5′-ATGGATGAAAAAAATCCAACAACAGAATTAAGTG-3′ | ||
| OPT3S1Rev | 5′-AACCAAGTTGGCAGCGGTATAG-3′ | ||
| OPT3S2For | 5′-GGACAGGATATTTACCAATCAACGATAATGG-3′ | ||
| OPT3S2Rev | 5′-CTAAGGGAAGTGACCAACTCTTGG-3′ | ||
| 4 | PTR2SeqFor | 5′-GTTCTTATTGTTACTTCAGCCTC-3′ | |
| 5 | PTR2SeqRev | 5′-GAGATAAGATGTATGTTTGCAAATGTC-3′ | |
| PTR22SeqFor | 5′-ATGTCCACAGAAGAGAAACATCTGCA-3′ | ||
| PTR22SeqRev | 5′-CTATGCATGGATTTGCGTGACGGAG-3′ | ||
Growth inhibitory in vitro activity of FMDP-oligopeptides against C. albicans wild type cells and oligopeptide transporters-deficient mutants, determined in YNB-SG medium.
| Strain | SC 5314 | |||||||
|---|---|---|---|---|---|---|---|---|
| F2 | 0.25 | 0.25 | 0.25 | 0.25 | 0.25 | 0.125 | >128 | >128 |
| F3 | 0.25 | 0.5 | 0.25 | 0.25 | 0.25 | 0.25 | >128 | >128 |
| F6 | 0.5 | 4 | 32 | 8 | 4 | 64 | 0.5 | 64 |
| F7 | 0.5 | 8 | 32 | 16 | 2 | 64 | 0.5 | 64 |
| P10 | 64 | 64 | 64 | 64 | 64 | 64 | 64 | 64 |
| F11 | 0.25 | 0.25 | 0.25 | 0.25 | 0.25 | 0.125 | >128 | >128 |
Growth inhibitory in vitro activity of FMDP-oligopeptides against C. albicans wild type cells and oligopeptide transporters-deficient mutants determined in YNB-AS medium.
| Strain | SC 5314 | |||||||
|---|---|---|---|---|---|---|---|---|
| F2 | 0.25 | 0.25 | 0.25 | 0.25 | 0.25 | 0.5 | >128 | >128 |
| F3 | 0.25 | 0.5 | 0.5 | 0.5 | 0.5 | 1 | >128 | >128 |
| F6 | 4 | 8 | 32 | 8 | 8 | >128 | 4 | >128 |
| F7 | 16 | 32 | >>128 | 32 | 32 | >128 | 16 | >128 |
| P10 | 64 | 64 | 64 | 64 | 64 | 64 | 64 | 64 |
| F11 | 16 | 32 | 128 | 32 | 16 | >128 | 16 | >128 |
Growth inhibitory in vitro activity of FMDP-oligopeptides against C. albicans wild type cells and oligopeptide transporters-deficient mutants determined in RPMI-1640 medium.
| Strain | SC 5314 | |||||||
|---|---|---|---|---|---|---|---|---|
| F2 | 8 | 64 | 32 | 64 | 32 | 64 | >128 | >128 |
| F3 | 8 | 16 | 16 | 16 | 16 | 16 | >128 | >128 |
| F6 | >128 | >128 | >128 | >128 | >128 | >128 | >128 | >128 |
| F7 | >128 | >128 | >128 | >128 | >128 | >128 | >128 | >128 |
| P10 | 64 | 64 | 64 | 64 | 64 | 64 | 64 | 64 |
| F11 | >128 | >128 | >128 | >128 | >128 | >128 | >128 | >128 |
Influence of supplementation of the YNB medium with the amino acid mixture (composition as in RPMI-1640) or L-glutamine (0.3 g L-1) on anticandidal in vitro activity.
| Growth medium | ||||
|---|---|---|---|---|
| YNB-SG | YNB + amino acid mixture | YNB + | YNB + | |
| F2 | 0.25 | 0.5 | 0.5 | 0.5 |
| F3 | 0.25 | 0.5 | 0.5 | 1.0 |
| F6 | 0.5 | >128 | 4.0 | 128 |
| F7 | 0.5 | >128 | 8.0 | 64 |
| P10 | 64 | 64 | 64 | 64 |
| F11 | 1.0 | >128 | 16 | >128 |
Initial uptake rates of FMDP-oligopeptides and model alanyl oligopeptides by C. albicans wild type cells and oligopeptide transporters-deficient mutants.
| Strain | SC 5314 | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| F2 | 4.83 ± 0.11 | 4.75 ± 0.09 | 4.80 ± 0.15 | 4.86 ± 0.14 | 4.78 ± 0.11 | 4.05 ± 0.18 | <0.1 | <0.1 | |
| F3 | 4.32 ± 0.14 | 4.08 ± 0.14 | 3.23 ± 0.19 | 4.12 ± 0.15 | 4.19 ± 0.16 | 2.98 ± 0.18 | 0.11 ± 0.04 | <0.1 | |
| P5 | 2.66 ± 0.19 | 2.01 ± 0.16 | 0.52 ± 0.08 | 1.95 ± 0.13 | 1.82 ± 0.11 | 0.39 ± 0.07 | 2.56 ± 0.18 | 0.15 ± 0.04 | |
| F6 | 3.12 ± 0.20 | 2.08 ± 0.15 | 0.56 ± 0.09 | 2.99 ± 0.11 | 2.03 ± 0.15 | 0.22 ± 0.04 | 3.00 ± 0.25 | 0.18 ± 0.03 | |
| P6 | 2.22 ± 0.11 | 1.85 ± 0.15 | 0.40 ± 0.09 | 2.11 ± 0.16 | 1.99 ± 0.10 | 0.22 ± 0.07 | 2.46 ± 0.19 | 0.12 ± 0.03 | |
| F7 | 2.40 ± 0.16 | 1.70 ± 0.12 | 0.46 ± 0.08 | 1.85 ± 0.12 | 1.44 ± 0.10 | 0.32 ± 0.07 | 2.22 ± 0.16 | 0.23 ± 0.02 | |
| P10 | <0.1 | <0.1 | <0.1 | <0.1 | <0.1 | <0.1 | <0.1 | <0.1 | |
| F11 | 2.25 ± 0.15 | 1.64 ± 0.11 | 0.22 ± 0.03 | 1.77 ± 0.18 | 1.92 ± 0.18 | 0.33 ± 0.04 | 2.28 ± 0.15 | 0.18 ± 0.02 | |
| (Ala)2 | 5.12 ± 0.32 | 4.50 ± 0.36 | 3.96 ± 0.29 | 4.83 ± 0.31 | 5.00 ± 0.38 | 5.88 ± 0.40 | <0.1 | <0.1 | |
| (Ala)3 | 5.62 ± 0.33 | 4.89 ± 0.28 | 4.16 ± 0.22 | 3.22 ± 0.27 | 3.61 ± 0.30 | 4.99 ± 0.36 | <0.1 | <0.1 | |
| (Ala)4 | 3.75 ± 0.19 | 0.79 ± 0.09 | 1.93 ± 0.15 | 1.72 ± 0.11 | 1.55 ± 0.11 | 0.12 ± 0.02 | 2.72 ± 0.16 | <0.1 | |
Anticandidal in vitro activity of FMDP-oligopeptides against isolates resistant to F2 and F3, determined in YNB-SG medium.
| Peptide | F2 | F3 | F6 | F7 | F11 |
|---|---|---|---|---|---|
| NF1 | >128 | 64 | 4 | 16 | 16 |
| NF2 | >128 | 128 | 4 | 16 | 32 |
| NF3 | 128 | 64 | 4 | 16 | 16 |
| LNF1 | >128 | >128 | 4 | 16 | 16 |
| LNF2 | >128 | >128 | 8 | 16 | 32 |
| LNF3 | >128 | 64 | 4 | 16 | 16 |
| SC5314 | 0.125 | 0.25 | 4 | 16 | 16 |
Stability of resistance to F2/F3 of NF1-3 and LNF1-3 isolates after 10 subsequent passages in YPD medium. MIC values were determined in YNB-SG.
| Peptide | F2 | F3 |
|---|---|---|
| NF1′ | >128 | 64 |
| NF2′ | 128 | 128 |
| NF3′ | 8 | 16 |
| LNF1′ | 0.125 | 0.5 |
| LNF2′ | 0.125 | 0.5 |
| LNF3′ | >128 | 64 |
| SC5314 | 0.25 | 0.25 |